Relationship between adjunctive medications for anxiety and time spent ill in patients with bipolar disorder

International Journal of Psychiatry in Clinical Practice

Volumn 13, Issue 1, 2009, Pages 70-77

  Bauer, Michael ^a   Glenn, Tasha ^b   Grof, Paul ^c,d   Rasgon, Natalie L ^e   Marsh, Wendy ^f   Sagduyu, Kemal ^g   Alda, Martin ^h   Lewitzka, Ute ^a   Schmid, Rita ⁱ   Whybrow, Peter C ^j  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ChronoRecord Association Inc   (United States)

^c Mood Disorders Clinic of Ottawa   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF REGENSBURG   (Germany)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Anxiolytics; Benzodiazepines; Bipolar disorder; Outcome

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; GABAPENTIN; HYDROXYZINE; PREGABALIN;

ADULT; ANXIETY; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 60749126046     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500802450514     Document Type: Article

References (68)

1. Bauer MS, Whybrow PC, Gyulai L, Gonnel J, Yeh HS. Testing definitions of dysphoric mania and hypomania: prevalence, clinical characteristics and inter-episode stability. J Affect Disord 1994;32:201-11.
2. Cassidy F, Murry E, Forest K, Carroll BJ. Signs and symptoms of mania in pure and mixed episodes. J Affect Disord 1998;50:187-201.
3. Maj M, Pirozzi R, Magliano L, Bartoli L. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am J Psychiatry 2003;160:2134-40.
4. Benazzi F, Koukopoulos A, Akiskal HS. Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). Eur Psychiatry 2004;19:85-90.
5. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005;85:245-58.
6. Henry C, M'Baïlara K, Poinsot R, Casteret AA, Sorbara F, Leboyer M, et al. Evidence for two types of bipolar depression using a dimensional approach. Psychother Psychosom 2007;76:325-31.
7. Pini S, Cassano GB, Simonini E, Savino M, Russo A, Montgomery SA. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. J Affect Disord 1997;42:145-53.
8. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50:143-51.
9. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002;68:1-23.
10. McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, Kennedy SH. Anxiety disorders and bipolar disorder: a review. Bipolar Disord 2006;8:665-76.
11. Frank E, Cyranowski JM, Rucci P, Shear MK, Fagiolini A, Thase ME, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry 2002;59:905-11.
12. Simon NM, Zalta AK, Otto MW, Ostacher MJ, Fischmann D, Chow CW, et al. The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res 2007;41:255-64.
13. MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord 2003;5:349-55.
14. Boylan KR, Bieling PJ, Marriott M, Begin H, Young LT, MacQueen GM. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 2004;65:1106-13.
15. Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 2006;189:20-5.
16. Feske U, Frank E, Mallinger AG, Houck PR, Fagiolini A, Shear MK, et al. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry 2000;157:956-62.
17. Henry C, Van den Bulke D, Bellivier F, Etain B, Rouillon F, Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry 2003;64:331-5.
18. Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 2007;104:137-46.
19. McElroy SL, Altshuler LL, Suppes T, Keck PE Jr, Frye MA, Denicoff KD, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158:420-6.
20. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004; 161:2222-29.
21. Young LT, Cooke RG, Robb JC, Levitt AJ, Joffe RT: Anxious and non-anxious bipolar disorder. J Affect Disord 1993;29:49-52.
22. Kauer-Sant'Anna M, Frey BN, Andreazza AC, Ceresér KM, Gazalle FK, Tramontina J, et al. Anxiety comorbidity and quality of life in bipolar disorder patients. Can J Psychiatry 2007;52:175-81.
23. Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, et al. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol 2004;24:512-20.
24. Bauer M, Glenn T, Grof P, Rasgon NL, Marsh W, Sagduyu K, et al. Relationship between subsyndromal symptoms and employment status in patients with bipolar disorder. Submitted manuscript.
25. Bauer MS, Crits-Christoph P, Ball WA, Dewees E, McAllister T, Alahi P, et al. Independent assessment of manic and depressive symptoms by self-rating. Scale characteristics and implications for the study of mania. Arch Gen Psychiatry 1991;48:807-12.
26. Whybrow PC, Grof P, Gyulai L, Rasgon N, Glenn T, Bauer M. The electronic assessment of the longitudinal course of bipolar disorder: The ChronoRecord software. Pharmacopsychiatry 2003;36(Suppl 3):S244-9.
27. Bauer M, Grof P, Gyulai L, Rasgon N, Glenn T, Whybrow PC. Using Technology to Improve Longitudinal Studies: Self-Reporting in Bipolar Disorder. Bipolar Disord 2004;6:67-74.
28. Bauer M, Wilson T, Neuhaus K, Sasse J, Pfennig A, Lewitzka U, et al. Self-reporting software for bipolar disorder: validation of ChronoRecord by patients with mania. Psychiatry Res 2008;159:359-66.
29. Bauer M, Glenn T, Grof P, Pfennig A, Rasgon NL, Marsh W, et al. Self-reported data from patients with bipolar disorder: frequency of brief depression. J Affect Disord 2007;101:227-33.
30. Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 2002;22:584-91.
31. Carta MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord 2003;75:83-91.
32. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998;155:992-3.
33. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
34. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder.J Clin Psychopharmacol 2000;20:467-71.
35. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.
36. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-30.
37. Denicoff KD, Smith-Jackson EE, Disney ER, Suddath RL, Leverich GS, Post RM. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res 1997;31:593-603.
38. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994;31:281-94.
39. Ghaemi SN: Anxiety and bipolar disorder. Medscape Family Medicine/Primary Care 2004;6.
40. Singh JB, Zarate CA Jr. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disord 2006;8:696-709.
41. Pillay SS. Polypharmacy of anxiety disorders. In: Ghaemi SN, editor. Polypharmacy in psychiatry. New York: Informa Healthcare; 2002. p 134-5.
42. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-33.
43. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-6.
44. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47.
45. Bauer M, Rasgon N, Grof P, Glenn T, Lapp M, Marsh W, et al. Do antidepressants influence mood patterns? A naturalistic study in bipolar disorder. Eur Psychiatry 2006;21:262-9.
46. Vieta E. Case for caution, case for action. Bipolar Disord 2003;5:434-5.
47. Benazzi F. Suicidal ideation and depressive mixed states. Psychother Psychosom 2005;74:61-2.
48. Benazzi F. Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states). Eur Psychiatry 2008;23:40-8.
49. Bowen RC, D'Arcy C. Response of patients with panic disorder and symptoms of hypomania to cognitive behavior therapy for panic. Bipolar Disord 2003;5:144-9.
50. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983;18:451-66.
51. Sachs GS. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990;51(Suppl 3):1-4.
52. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992;53:47-52.
53. Schatzberg, AF, Cole J, Debattista C. Manual of clinical psychopharmacology. 4th ed. Washington, DC: American Psychiatric Association; 2002. p 305-7.
54. Goodwin FK, Jamison KR: Manic-depressive illness. New York: Oxford University Press; 1990. p 665-724.
55. Winkler D, Willeit M, Wolf R, Stamenkovic M, Tauscher J, Pjrek E, et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. Eur Neuropsychopharmacol 2003;13:129-34.
56. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003;54:1395-401.
57. Salzman C. Benzodiazepine dependence, toxicity and abuse: A Task Force of the American Psychiatric Association. American Psychiatric Association: Washington DC; 1990.
58. Hwang G, Kim HR, Park SH, Kim SH, Park SR, Kim GH. Do benzodiazepines extend the duration of follow-up treatment in patients with bipolar disorder? Hum Psychopharmacol 2006;21:319-25.
59. Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry 2008;69:609-16.
60. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W; for the BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:355-62.
61. Zimmerman M, Posternak M, Friedman M, Attiullah N, Baymiller S, Boland R, et al. Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry 2004;161:1285-9.
62. Zutshi A, Reddy YC, Thennarasu K, Chandrashekhar CR. Comorbidity of anxiety disorders in patients with remitted bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2006;256:428-36.
63. MacKinnon DF, Zandi PP, Cooper J, Potash JB, Simpson SG, Gershon E, et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002;159:30-5.
64. Rotondo A, Mazzanti C, Dell'Osso L, Rucci P, Sullivan P, Bouanani S, et al. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 2002;159:23-9.
65. Tohen M, Bowden CL, Calabrese JR, Lin D, Forrester TD, Sachs GS, et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry 2006;189:515-19.
66. Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008;65:386-94.
67. Altshuler LL, Post RM, Black DO, Keck PE Jr, Nolen WA, Frye MA, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry 2006;67:1551-60.
68. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007;9:183-96.